ArticleOncotarget2018

Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.

Emily Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.